Answers are grounded in this paper and cite their sources.
PURPOSE: To analyze the cost-effectiveness of needle core biopsy (NCB) in a breast cancer screening program. MATERIALS AND METHODS: A computer model was used to compare two hypothetical groups of women: those who undergo annual mammographic screening and those observed without screening. All clinically significant outcomes for each group were included in the model, which reflected the state of a woman's health each year beginning at age 40 years and ending at age 85 years. RESULTS: The marginal cost per year of life saved by screening was reduced a maximum of 23% (from $20,770 to $15,934) with use of NCB instead of surgical biopsy. The cost of NCB had less effect on cost-effectiveness than the number of women who underwent NCB. CONCLUSION: When used for the same indications as surgical biopsy, NCB substantially reduces the cost of a breast cancer screening program.
No takes yet. Share an insight, caveat, or question.
Lindfors et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: